Difference between revisions of "Team:Sheffield/Integrated Practices"

Line 322: Line 322:
 
We did not simply make conclusions on the stakeholders’ needs through researching secondary sources but actually went out and spoke to different stakeholders personally.
 
We did not simply make conclusions on the stakeholders’ needs through researching secondary sources but actually went out and spoke to different stakeholders personally.
 
</P>
 
</P>
−
<!--
+
 
−
<p>
+
−
We first got in touch with <b>Professor Milton Wainwright, author of “Miracle Cure: The Story of Penicillin and the Golden Age of Antibiotics” </b>, to understand the history of antibiotics and <b> Dr. Jolian McHardy, an Economics lecturer at the University of Sheffield </b>,  to learn the economics of misusing antibiotics. These conversations allowed us to have better knowledge on antibiotic resistance.
+
−
</p>
+
−
<p>
+
−
Next, we researched on how our device would fit in the world. In terms of the parts of the world that would benefit from our project, we see it can be broken down to two levels: policy making by people of influence and policy implementation by people on ground. There is an interaction between these people within each level and in between the levels as well. This is studied by Political science and thus, we spoke with <b>Dr. Simon Rushton, a Politics lecturer and coauthor of “Disease diplomacy: International norms and global health security”</b>. Speaking with Dr. Rushton motivated us to identify the stakeholders and the dynamics among our stakeholders.
+
−
</p>
+
−
<p>
+
−
We wanted to know on a more personal level, what these stakeholders wanted from our proposed device. We therefore contacted <b>Mr. David Oglesby, member of the UK AMR steering group</b>, to check our understanding of the needs of the <b>UK government</b>.
+
−
</P>
+
−
<p>
+
−
However, just listening to the voice of the government would not be sufficient as the end users of our device would be the patients and doctors. As such, we interviewed <b>Dr. Sarah Thompson, Director of Infection Prevention & Control at Sheffield Children’s Hospital and Mr. Paul Slater, a patient suffering from vancomycin-resistant enterococci.</b>
+
−
</p>
+
−
<p>
+
−
Furthermore, potential end users of our device also include animals. <b>Professor Andrew Rycroft, Professor and Veterinarian at the Royal Veterinary College</b>, provided us an interesting insight on the design of this device and the scope of the veterinary use of antibiotics.
+
−
</P>
+
−
-->
+
 
<p>
 
<p>
 
We did more than just interview experts and stakeholders. To explore how we expanded  and see how we integrated stakeholders’ opinions in the design of our project, please see the sections below. </p>
 
We did more than just interview experts and stakeholders. To explore how we expanded  and see how we integrated stakeholders’ opinions in the design of our project, please see the sections below. </p>

Revision as of 12:29, 18 October 2016

A template page

HUMAN PRACTICES

Overview

Our work in human practices is set out to study the societal implications of our project. The findings informed our understanding of antibiotic resistance as a problem. Most importantly, this was then used to improve the design of our project beyond a pure biological and engineering point of view, but from a point of view of the stakeholders. We achieve this by modifying our design to their needs.

We did not simply make conclusions on the stakeholders’ needs through researching secondary sources but actually went out and spoke to different stakeholders personally.

We did more than just interview experts and stakeholders. To explore how we expanded and see how we integrated stakeholders’ opinions in the design of our project, please see the sections below.

EPISODE 1:

ANTIBIOTIC CULTURE

EPISODE 2:

BRAINSTORMING

EPISODE 3:

GLOBAL POLICIES

EPISODE 4:

UK STRATERGIES

EPISODE 5:

END USERS-HOSPITALS

EPISODE 6:

END USERS-AGRICULTURE

EPISODE 7:

END USERS-PATIENTS

EPISODE 8:

OUTREACH

FUTURE WORK